Report
Pharma Mar : Q2 earnings above
>Momentum, albeit still weak, improves sequentially - Total revenues receded just -1% y-o-y in Q2 2023 (vs -60% in Q1 2023, -40% in Q4 2022 and -3% in Q3 2022) and was broadly in line with our numbers and the consensus. Biopharma sales decreased -2% y-o-y in Q2 2023 (compared to -50% in Q1 2023, -44% in Q4 2022 and -18% in Q3 2022) reflecting lower Yondelis revenues (forced price reduction after the patent cliff) and an imposed price reduction in Zepzelca’s early acc...
Underlying
Pharma Mar SA
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.